Medivir Q2 2023 - Positive Signals from Fully Recruited Phase II
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2023-08-21 13:40:00
In August, the Lenvima arm of the phase II study of fostrox in advanced liver cancer was fully recruited. Positive signals are emerging from readouts of the first ten patients. The first readout from all 15 patients will be published within a few months, which will be a major catalyst for the company.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/